Scientific Program

*Subject to changes
WEDNESDAY MAY 23rd, 2018

13:00-15:00  Registration

14:00-15:00  Light Lunch at Registration area

15:00  Room Check in

15:00-17:00  Liver Forum: Case presentations and discussion
  Moderator: Dr. Yoav Luria

15:00-15:30  Much Mystery around HISTORt(i)
  Dr. Yaakov Maor, Institute of Gastroenterology & Hepatology, Kaplan Medical Center

15:30-16:00  כשהכבד פוגש את הכליה
  Dr. Yana Davidov, Liver Disease Center, Sheba Medical Center

16:00-16:30  Dr. Ella Veitzman, Liver Unit, Rambam Health Care Campus

17:00-17:30  Coffee Break and visit at the Medical Exhibition

17:30 -17:40  Welcome greetings
  Prof. Eli Zuckerman, Chair, IsASL

17:40-19:48  SESSION 1:
  Drug-Induced Liver Injury (DILI) and Liver Fibrosis
  Chairs: Dr. Ehud Zigmond, Dr. Ohad Etzion

17:40-17:52  Immunotherapy-induced hepatitis: clinicopathological characterization in a series of four cases.
  Afif Yaacob, Tarek Saadi, Ella Veitzman
  Liver Unit, Rambam Health Care Campus, Israel
17:52-18:04 Epigallocatechin 3-Gallate ameliorates lipid and liver injury profile through activation of NK cells in mice model of cholestatic liver fibrosis
Johnny Amer, Ahmad Salhab, Rifaat Safadi
Liver Unit, Hadassah Ein – Kerem, Jerusalem, Israel

18:04-18:16 Macrophage-derived COMMD10 plays important protective role in the resolution of acetaminophen-induced liver injury
Keren Cohen¹,², Odelia Mouhadeb¹,², Shani Ben Shlomo¹, Nathan Gluck¹, Chen Varol¹,²
¹The research center for digestive tract and liver diseases, Sourasky medical center, Israel
²Department of clinical microbiology and immunology, Sackler faculty of medicine, Tel-Aviv University, Israel

18:16-18:46 Update from EASL: DILI Guidelines 2018
Prof. Oren Shibolet, Director, Gastroenterology Unit, Tel Aviv Medical Center, Israel

18:46-18:58 Liver injury induced by immune checkpoint inhibitors is patient’s oriented and is associated with different histological findings
Yana Davidov¹,², Oranit Cohen-Ezra¹,², Ella Veitsman¹,², Maria Lihter¹, Itai Kalisky¹,², Ziv Ben-Ari¹,²
¹Liver Diseases Center, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
²Sackler School of Medicine, Tel Aviv University, Israel

19:00-19:12 The direct effect of the citric acid cycle on hepatic stellate cell activation and on the development of liver fibrosis
Landesman H¹,², Tachlytski I¹, Masoud R¹, Ben-Ari Z¹,², Safran M¹
¹Liver Diseases Center, ²Sackler School of Medicine, Tel Aviv University, Tel Aviv
19:12-19:24 Sodium taurocholate co-transporting polypeptide (NTCP) as novel checkpoint in NK cells activity in Liver fibrosis
Johnny Amer, Ahmad Salhab, Rifaat Safadi
Liver Unit, Hadassah Ein – Kerem, Jerusalem, Israel

19:24-19:36 Leukemia inhibitory factor induces cholangiocyte proliferation and corrects the impaired bile duct morphogenesis in sortilin-deficient mice following cholestatic liver injury
Einav Hubel-Manor¹, roy Avraham¹, Elise G Lavoie², Jonathan A Dranoff², Isabel Zvibel¹, Oren Shibolet¹
¹The Research Center for Digestive Tract and Liver Diseases, Tel-Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Israel
²Division of Gastroenterology & Hepatology, University of Arkansas for Medical Sciences, USA

19:36-19:48 The Effectiveness of Measuring Thiopurines Metabolites in Adult Patients with Autoimmune Hepatitis
Tarek Saadi, Worood Yassin, Rimma Kramsky, Afif Yaacob, Vered Ben-Hakoon, Hisham Sholy, Ella Veitzman
Liver Unit, Rambam Health Care Campus, Israel

THURSDAY MAY 24th, 2018

08:15-10:35 SESSION 2:
Liver Cancer and transplantation
Chairs: Dr. Yoram Menachem, Dr. Izhar Levi

08:15-08:27 Hepatitis C virus leaves an epigenetic signature following cure of infection by direct-acting antivirals
Meital Gal- Tanami, Medicine, BIU, Israel

08:27-09:02 Genetic signature of HCC: clinical applications
Prof. Jessica Zucman-Rossi, University Paris Descartes, France
09:02-09:14  **Hypophosphatemia as an early postoperative indicator of decreased major complications rate after liver resection for colorectal liver metastases**

_Yael Berger_¹, Eviatar Nesher¹, Riad Haddad¹, Shlomit Tamir², Natalia Goldberg², David Aranovich¹, Daniel Benchimol¹, Hanoch Kashtan¹, Eran Sadot¹

¹Surgical Unit, Beilinson Hospital, Israel
²Radiology, Beilinson Hospital, Israel

09:14-09:26  **Fecal microbiota profiles as a diagnostic biomarker in cirrhosis and hepatocellular carcinoma and the impact of lifestyle and nutrition**

Lapidot L¹,⁴, Amir A, Nosenko R⁵, Gayshis B², Likhter M², Ben-Ami D², Harnoy O², Engel T², Kalisky I², Weiss P², Veitsman E², Cohen-Ezra O², Davidov Y², Segev S², Koren O⁵, _Safran M_¹,², Ben-Ari Z¹,²,⁴.

¹Liver Research Laboratory, ²Liver Diseases Center, ³Medical Screening Unit, Chaim Sheba Medical Center – Tel Hashomer ⁴The Sackler School of Medicine, Tel Aviv University, Tel Aviv, ⁵Faculty of Medicine, Bar-Ilan University, Safed

09:26-09:38  **Are Patients Treated with Direct Antiviral Agents for HCV Infection at Greater Risk for Extrahepatic Malignancies?**

_Tarek Saadi_, Rimma Kramsky, Afif Yaacob, Hisham Sholy, Faheem Shehadeh, Vered Ben-Hakoon, Ella Veitzman, Jihad Khoury

Liver Unit, Rambam Health Care Campus, Israel

09:38-09:50  **Prevalence and outcomes of a second extrahepatic malignancy among patients with Hepatocellular Carcinoma in an Israeli cohort**

_Yoram Menachem_, Oren Shibolet, Hadar Maringer

Liver Unit, Sourasky Medical Center, Ichilov Hospital, Tel- Aviv, Israel
Resection versus transplant listing for hepatocellular carcinoma in Israel: an intention to treat analysis
Guy Meyerovich¹,³, Ido Nachmany¹,³, Yaacov Goykhman¹, Richard Nakache¹,³, Oren Shibolet²,³, Yoram Menachem², Helena Katsman², Rafael Bruck², Nir Lubezky¹,³
From the department of surgery¹ and the institute of Gastroenterology², Tel Aviv Medical Center, Sackler School of Medicine³, The Nicholas and Elizabeth Cathedra of Experimental Surgery, Tel Aviv University, Israel

Liver transplantation for hepatocellular carcinoma through the lens of transplant benefit
Prof. Umberto Cillo, Director, Hepatobiliary & Liver Transplantation Unit, University of Padova, Italy

Sponsored by NOVARTIS

Coffee Break and visit at the Medical Exhibition

SESSION 3:
HCC and liver transplantation II (continued)
Chairs: Dr. Rawi Hazan, Dr. Marius Braun

Resection of HCC in cirrhotics
Dr. Riad Haddad, Carmel Medical Center

Case presentation (HCC in cirrhotic patient and discussion):
Presenter TBA
Discussion: Down staging, loco-regional treatment, transplantation, anti viral treatment
Panel: Prof. Daniel Azoulay, Prof. Eythan Mor and Prof. Umberto Cillo
11:40-11:52  **Meso-Rex bypass for Hilar cancer type 3A – Surgical Innovation with a Multidisciplinary treatment approach.**  
**Eylon Lahat**¹, Jabar Ahmad¹, Ziv Ben Ari³, Gil Golan⁴, Mordechi Gutman¹, Daniel Azoulay¹,²  
¹Surgery B and hepatobiliary and pancreatic surgery, Tel Hashomer hospital, Israel  
²Hepatobiliary pancreatic and liver transplantation, Henri Mondor hospital, France  
³Center of liver disease, Tel Hashomer hospital, Israel  
⁴Invasive Radiology, Tel Hashomer hospital, Israel

11:55-12:15  **Living related donor liver transplantation: The Israeli Experience**  
**Prof. Eythan Mor,** Rabin Medical Center, Israel

12:15-12:45 **SESSION 4:**  
**State of the art lecture**  
**Chairs: Dr. Alice Hershkovitz, Dr. Yona Kitay**

12:15-12:45  **Spatial transcriptomics of the mammalian liver**  
**Dr. Shalev Itzkovitz,** Department of molecular cell biology, Weizmann Institute, Israel

12:45-13:45 **Lunch & Visit at the Medical Exhibition**

13:45-16:20 **SESSION 5:**  
**Cirrhosis and Liver Fibrosis I**  
**Chairs: Prof. Rifaat Safadi, Dr. Matthias Karlebach**

13:45-14:05  **Surgery in patients with chronic liver disease**  
**Prof. Adrian Reuben,** Prof. of Medicine Emeritus ‘15, MUSC, USA
Acute hemodynamic response to I.V propranolol during hepatic hemodynamic study in 26 cirrhotic patients with portal hypertension and nonbleeding esophageal varices. Correlation with esophageal bleeding and survival.

Eyal Ashkenazi, Yulia Kovalev, Alex Haimovich, Eli Zuckerman
Liver Unit, Carmel Medical Center; Haifa, Israel

Prevalence of minimal hepatic encephalopathy in the patients with fatty liver disease: a pilot study

Nir Bar, Shira Deri, Jenny Rutenburg, Oren Shibolet, Helena Katchman
Gastroenterology department, Tel Aviv Sourasky Medical Center, Israel

Liver Cirrhosis, changing of the etiology

Naim Abu-Freha¹, Najwan Kial², Muhammad Abu Tailakh³, Ali Elsana⁴, Alexander Fich¹, Heba Abu Kaf⁵, Ohad Etzion¹
¹ The Institute of Gastroenterology and Hepatology, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, the Arab Medical Association in the Negev, Beer-Sheva, Israel
² Internal Medicine Ward C, Soroka University Medical Center; Beer-Sheva, Israel
³ Nursing Research Unit, Soroka University Medical Center
⁴ Internal Medicine Ward A, Soroka University Medical Center; Beer-Sheva, Israel

Placement of TIPS prior to surgery in patients with portal hypertension

Prof. Daniel Azoulay, Senior Surgeon, The Center for Liver Diseases, Sheba Medical Center, Israel

The Role of Eosinophils in CCl4 induced Liver Fibrosis

Itay Moshkovitz, Ayelet Kaminitz, Debby Reuveni, Chen Varol, Chen Varol, Oren Shibolet, Ehud Zigmond
Tel-Aviv Sourasky Medical Center, The Research Center for Digestive Tract & Liver Diseases, Israel
Endoscopic Ultrasound-Guided Angio-Therapy for Gastric Varices: A Single Center Experience

Idiopathic non-cirrhotic portal hypertension: clinical and hemodynamic characteristics and outcome of a cohort of 18 patients

Management of non-tumoral PVT in in candidates to liver transplantation

The Journey of Sofosbuvir: from a molecule to a drug
Treatment of hepatitis C among HIV HCV coinfected patients in a real world setting – on the path to HCV elimination in a single center

Ella Veitsman¹, Tarek Saadi¹,³, Afif Yacoub¹, Rimma Kramsky¹, Vered Ben-Hakoon¹, Yaacov Baruch¹,³, Margalit Lorber²,³, Jamal Hassoun², Einat Kedem², Eduardo Shahar²,³

¹Center for Liver Diseases, Rambam Health Care Campus, Israel
²Institute of Immunology, Allergy and AIDS, Rambam Health Care Campus, Israel
³Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel

Update from EASL 2018, HCV guidelines 2018

Prof. Eli Zuckerman, Chair, IsASL

HCV elimination Program in Israel: to where we are going?

Mr. Julio Borman, Hetz- Israeli Patients’ organization

Awake the dormants: barriers to access to care and cure in patients with chronic HCV infection

Orly Azulay, Eyal Ashkenazi, Yulia Kovalev, Eli Zuckerman
Liver Unit, Carmel Medical Center, Technion, Faculty of Medicine, Haifa, Israel

Emerging Therapies for hepatitis B: What is expected in the near future?

Prof. Ran Tur-Kaspa, Liver Institute, Rabin Medical Center, Faculty of Medicine in the Galilee, Bar Ilan University, Israel
Real life experience with direct acting antiviral agents in patients with chronic hepatitis C and inherited bleeding disorders

Yana Davidov\textsuperscript{1,2}, Oranit Cohen-Ezra\textsuperscript{1,2}, Ella Veitsman\textsuperscript{1}, Avishag Hassid\textsuperscript{1}, Dana Silverberg\textsuperscript{1}, Adi Halle-Bikovski\textsuperscript{1}, Keren Tzaraf\textsuperscript{1}, Ziv Ben-Ari\textsuperscript{1,2}

\textsuperscript{1}Liver Diseases Center; Sheba Medical Center; Tel Hashomer; Ramat Gan, Israel
\textsuperscript{2}Sackler School of Medicine, Tel Aviv University, Israel

Circulation of hepatitis E in Israel: high prevalence in pigs, Dromedary camels and in specific human populations

Rachel Shirazi\textsuperscript{1}, Shaul Pozzi\textsuperscript{2}, Ravit Bassal\textsuperscript{3}, Dan David\textsuperscript{2}, Marina Wax\textsuperscript{1}, Itay Bar-Or\textsuperscript{1}, Efrat Asulin\textsuperscript{1}, Yaniv Lustig\textsuperscript{1}, Eli Schwartz\textsuperscript{4,5}, Hazzan Rawai\textsuperscript{6}, Ella Mendelson\textsuperscript{1,5}, Ziv Ben-Ari\textsuperscript{5,7}, Orna Mor\textsuperscript{1,5}

\textsuperscript{1}Central Virology Laboratory, Ministry of Health, Israel
\textsuperscript{2}Veterinary services, Agriculture Ministry, Israel
\textsuperscript{3}Israel Center for Disease Control, Ministry of Health, Israel
\textsuperscript{4}Tropical Diseases, Sheba Medical Center, Israel
\textsuperscript{5}Sackler Faculty of Medicine, Tel Aviv University, Israel
\textsuperscript{6}Liver unit, Haemek Medical Center, Israel
\textsuperscript{7}Liver unit, Sheba Medical Center, Israel

Liver steatosis predicts mortality and cancer in patients with chronic hepatitis B infection and is inversely correlated with viral replication

Noam Peleg\textsuperscript{1}, Assaf Issachar\textsuperscript{1,2,3}, Michal Cohen-Naftaly\textsuperscript{2,3}, Orly Sneh-Arbib\textsuperscript{2,3}, Marius Brown\textsuperscript{2,3}, Amir Shlomai\textsuperscript{1,2,3}

\textsuperscript{1}Internal medicine D, Rabin Medical Center, Israel
\textsuperscript{2}Institute of Liver Disease, Rabin Medical Center, Israel
\textsuperscript{3}Sackler Faculty of Medicine, Tel Aviv University, Israel
High frequency of multiclass HCV resistance to second-generation direct-acting antiviral failure in Israel real-life: tailored therapies are advocated

Ziv Ben-Ari1,3, Yael Gozlan2, Rachel Shirazi2, Aviya Rakovsky2, Yana Davidov1, Ella Veitsman4, Tarek Saadi4, Marius Braun3,5, Michal Cohen-Naftaly3,5, Amir Shlomai3,5, Oren Shibolet3,6, Ehud Zigmond3,6, Helena Katchman3,6, Yoram Menachem3,6, Rifaat Safadi7, Eitan Galun7, Eli Zuckerman8, Assy Nimer9, Rawi Hazzan10, Yaakov Maor1, Sayaf Abu-Moch12, Ohad Etsion13, Yoav Lurie14, Orna Mor2,3

1 Liver unit, Sheba Medical Center, Israel
2 Central Virology Laboratory, Ministry of Health, Israel
3 Sackler Faculty of Medicine, Tel Aviv University, Israel
4 Liver unit, Rambam Medical Center, Israel
5 Liver unit, Rabin Medical Center, Israel
6 Department of Gastroenterology, Tel-Aviv Medical Center, Israel
7 Liver unit, Hadassah Medical Center, Israel
8 Liver unit, Carmel Medical Center, Israel
9 Internal Medicine department, Galilee Medical Center, Israel
10 Liver unit, Haemek Medical Center, Israel
11 Division of Gastroenterology, Kaplan Medical Center, Israel
12 Liver unit, Hillel Yafe Medical Center, Israel
13 Liver unit, Soroka Medical Center, Israel
14 Liver unit, Shaare Zedek Medical Center, Israel
פורום אחיות Ced 2018 אילת

Sponsored by Neopharm Israel

08:00-09:30 PARALLEL SESSION FOR NURSES - CORAL HALL

הThêmות

07:50

הרצאת פתיחה: "המחלת PBC" - מקורה לידינו ב PBC

08:00

פרופ’ יוסי צוקרמן, מנוהל מכון הכבד במרכז הרפואӣ כרמל ויו”ר התכנסות

08:50

كرم צארץ, אחראי אחות במרכז למחולות כבד, מרכז רפואӣ שיבא

09:10

"PBC" תפקידי האחות ב PBC

كرم צארץ, אחראי אחות במרכז למחולות כבד, מרכז רפואӣ שיבא

09:30

מקורה לידינו ב OCALIVA

ד”ר אורית כהן，则אר, מרכז למחולות כבד, מרכז רפואӣ שיבא

09:50

פעילותümמורת כבד.Hidden מהלוכל לוטואימוניות של הכבד

וב’ סיני, ידיבריים, عمורות כבד

10:10

דברי סיום

גב’ אורה אשכול, אחראית אחות מחולים מותאימים מחקרים מכון הכבד, מרכז רפואӣ כרמל
Portal Lymphadenopathy Predicts Steatohepatitis and Advanced Fibrosis in Non-alcoholic Fatty Liver Disease

Serum sRAGE levels are associated with lifestyle and with non-alcoholic fatty liver disease

Reduced PI3K pathway in NK cells of F4-NAFLD patients inhibited mTOR expressions and was correlated with their impaired function

Quantification of Hepatic Fat – Ultrasound, Biomarkers and MR Spectroscopy
Noninvasive scoring systems predict long-term morbidity, mortality and cancer in patients with nonalcoholic fatty liver disease

Update from EASL: NASH and emerging therapies
Prof. Ziv Ben-Ari, Liver Unit, Sheba Medical Center, Israel

Screening Diabetic Patients for Non-alcoholic Fatty Liver Disease (NAFLD) - Is it Cost-Effective?
Yaakov Maor¹, Shira Zelber-Sagi²,³, Moshe Leshno⁴
¹Institute of Gastroenterology and Hepatology, Kaplan Medical Center, Israel
²Department of Gastroenterology and Liver Diseases, Tel Aviv Medical Center, Israel
³School of Public Health, University of Haifa, Israel
⁴Coller School of Management, Tel Aviv University, Israel

The pattern of elevated liver function tests in non-alcoholic fatty liver disease predicts fibrosis stage and metabolic-associated comorbidities
Dor Shirin¹, Noam Peleg¹,², Orly Sneh-Arrib², Michal Cohen-Naftaly², Marius Braun²,³, Assaf Issachar¹,² and Amir Shlomai¹,²,³
¹ Department of Medicine D, Rabin Medical Center, Beilinson hospital, Petah-Tikva, Israel
² The Liver Institute, Rabin Medical Center, Beilinson hospital, Petah-Tikva, Israel
³ The Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
**10:10-10:22**  
NAFLD fibrosis score predicts diabetic complications in patients with NAFLD  
Noam Peleg¹, Assaf Issachar²,³, Sneh-Arhib Orly²,³, Michal Cohen-Naftaly²,³, Marius Brown²,³, Amir Shlomai²,³  
¹Internal medicine D, Rabin Medical Center, Israel  
²Institute of Liver Disease, Rabin Medical Center, Israel  
³Sackler Faculty of Medicine, Tel Aviv University, Israel

**10:22-10:40**  
Coffee Break and visit the Medical Exhibition

**10:40-10:45**  
Awards for outstanding clinical study, basic science study & poster

**10:45**  
SESSION 9:  
Cirrhosis and Liver fibrosis II  
Chairs: Dr. Tarek Saadi, Dr. Ella Weitzman

**10:45-11:05**  
Kidney injury in patients with cirrhosis  
Prof. Adrian Reuben, Prof. of Medicine Emeritus ‘15, MUSC, USA

**11:05-11:17**  
Hepatocyte-secreted exosomes can inhibit and reverse hepatic stellate cells stimulation  
Ben-Ari Ziv¹,³, Masoud Rola¹, Sultan Maya¹, Tachlytski Irena¹, Balint-Lahat Nora², Pappo Orit², Safran Michal¹  
¹Liver Diseases Center, ²Pathology department Chaim Sheba Medical Center Sackler School of Medicine, Tel Aviv University, Tel Aviv  
³Sackler School of Medicine, Tel Aviv University, Tel Aviv

**11:17-11:29**  
COMMD10 is important for Kupffer cell elimination of Staphylococcus aureus  
Chen Varol, Shani Ben Shlomo, Odelia Mouhadeb, Nathan Gluck  
The Research Center for Digestive Tract & Liver Diseases, Sourasky Medical Center and Tel Aviv University, Israel
11:30-11:42  Liver Cirrhosis, Etiology and Clinical Characteristics Disparities among minority population
Muhammad Abu Tailakh², Liat Poupko³, Najwan Kial⁴, Ali Elsana⁵, Ohad Etzion¹, Heba Abu Kaf¹, Alexander Fich¹, David Yardni¹, Anat Nevo-Shor¹, Abed Abu Ganim⁶, Naim Abu-Freha¹
¹ Nursing Research Unit, Soroka University Medical Center, Epidemiology Department, Ben-Gurion University, Beer-Sheva, Israel
² 1st years student, Medical School for International Health, Ben-Gurion University, Beer-Sheva, Israel
³ Internal Medicine Ward C, Soroka University Medical Center, Beer-Sheva, Israel.
⁴ Internal Medicine Ward A, Soroka University Medical Center, Beer-Sheva, Israel.
⁵ The Institute of Gastroenterology and Hepatology, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel
⁶ Surgical Ward A, Soroka University Medical Center, Beer-Sheva, Israel.

11:42-11:54  The anti fibrotic effect of Aramchol on rat liver fibrosis induced by TAA and in vitro on primary hepatic stellate cells.
Regina Golan-Gerstl, Nickolay Koroukhov, Rawand Khweiss, Shimon Reif
Pediatrics Department, Hadassah Medical Center, Israel

11:54-12:06  Elevated expressions of Sodium taurocholate co-transporting polypeptide (NTCP) on NK cells impaired their function and contribute to liver fibrosis
Johnny Amer, Rifaat Safadi, Ahmad Salhab
Liver Unit, Hadassah Ein Kerem Hospital, Israel

12:06-12:25  Business Meeting
INVITED SPEAKERS

**Prof. Jessica Zucman-Rossi**, University Paris Descartes
Jessica Zucman-Rossi is Professor of Medicine at University Paris Descartes, within the department of Oncology at the European Hospital Geaorges Pompidou (AP-HP). She is the director of an INSERM laboratory “Functional Genomics of Solid Tumors”, with a focus on liver, mesothelial and renal tumors. Her team aims to develop basic genomic approaches based on human tumors analyses to identify new mechanisms of tumorigenesis and to transfer this knowledge into biomarkers that could be introduced in clinical care. In particular, the group was pioneer in the elucidation of the molecular classification of benign and malignant liver tumors. Currently, she is executive secretary of ILCA (International Liver Cancer Association) and she acts as co-Editor for Journal of Hepatology.

**Prof. Adrian Reuben**
Adrian Reuben is Professor of Medicine Emeritus’15 at the Medical University of South Carolina (MUSC), in Charleston SC, where, during 1993-2014, he directed the Liver Program he created.

Dr. Reuben graduated in Medicine, completed Residency and Gastroenterology Fellowship in London UK, before completing a scholarship at Yale. After a Yale faculty appointment (1981-1993), he moved to MUSC to establish the Liver Service and enhance the fledgling Liver Transplant (LT) program.

His continues research on Acute Liver Failure (ALF), Coagulopathy in Liver Disease, Alcohol
Biomarkers, Non-Invasive Investigation of Liver Disease and Drug Hepatotoxicity. He has considerable experience in LT, portal hypertension and he edited the May 2015 issue of Clinics in Liver Disease on Hepatocellular Carcinoma. He previously pursued laboratory-based investigation of biliary lipid secretion, and hepatic fibrogenesis. He has published 100+ peer-reviewed articles, editorials, case reports, and book chapters, as well as 44 essays in the acclaimed Landmarks in Hepatology series.

He has presented at national and international meetings, taught in postgraduate courses and workshops, and lectured in three continents. His participation in American Association for the Study of Liver Diseases (AASLD) committees, includes the Ethics Committee of which he was also the Chair. He continues to lecture, perform and publish research, review manuscripts and grant applications, and write chapters and reviews. His interest in drug hepatotoxicity is exemplified by an original article in HEPATOLOGY, on Drug-Induced Liver ALF in the United States, chapters in hepatotoxicity textbooks and membership of the Hepatotoxicity Special Interest Group Steering Committee of the AASLD. He has also first-authored a recent 16-year overview of ALF experience by the US ALF Study Group, published in April 2016 in Annals of Internal Medicine. Finally, he has very close connections with Medicine in Israel, and with Israeli Hepatology in particular. He and his late wife spent a delightful 6-month sabbatical at Hadassah in 2011/2012, and he continues to visit Israel frequently, when he lectures and teaches at major Israeli medical centers. He also has reasonable conversational Hebrew.

Prof Umberto Cillo, MD, FEBS, Professor of General Surgery
Director, Hepatobiliary and Liver Transplantation Unit
University of Padova, Italy

He is Professor of General Surgery at the Department of General Surgery, University of Padova since 2011 and Director of the Hepatobiliary and Liver Transplantation Unit, Department of General Surgery at the University of Padova since 2004. He is President of the Italian Society of Organ Transplantation (SITO) and the Italian representative of the European Board of Surgery, section of Transplantation (UEMS). Member of ESOT (European Society for Organ Transplantation) Council.

He will be President of the ESOT (European Society for Organ Transplantation) Congress in Milan, 2021.

Prof Cillo has performed as first surgeon/tutored over 3500 interventions of general surgery, over 1000 liver transplants, more than 140 cases of pediatric liver transplantation including split child-adult and adult-adult, living donor. He performed the first auxiliary liver transplantation in Italy (2007) and the first liver autotransplantation (2011) in Italy.

Since 2004 more than 2300 liver resections, 1200 liver transplants and 3600 liver ablations have been performed in his Unit.

Prof Cillo is first author or co-author of 277 reviewed publications, 18 chapters and 4 monographs. I.F. (JCR) 1213,626, H-INDEX 40 (Scopus), 48 (Google Scholar).